Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
PMCB Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: March 18, 2026
Report Source: 2026 3rd Quarter Report
PharmaCyte Biotech Inc. Stock Analysis PMCB
United States Health Care Nano Cap Report: PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Read More PharmaCyte Biotech Inc (PMCB) Chart
Key Statistics of PharmaCyte Biotech Inc (PMCB)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.76Volume
78.22KP/E Ratio (TTM)
0.2752 Week Range
Market Cap
8.55MAvg. Volume
140.85KDividend Yield
-Financial Metrics & Statements of PharmaCyte Biotech Inc (PMCB)
FAQ's for PharmaCyte Biotech Inc (PMCB)
- According to Musaffa’s Shariah screening methodology, PharmaCyte Biotech Inc (PMCB) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes PharmaCyte Biotech Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in PharmaCyte Biotech Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of PharmaCyte Biotech Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of PharmaCyte Biotech Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of PharmaCyte Biotech Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.